#454 Kidney Boy on Managing Diabetes and Hypertension in CKD
Sep 23, 2024
auto_awesome
Join nephrologist Joel Topf, also known as Kidney Boy, as he shares his expertise on managing diabetes and hypertension in chronic kidney disease. He discusses key strategies for controlling blood pressure, the importance of timely referrals, and the latest updates in CKD management guidelines. Delve into innovative treatments like SGLT2 inhibitors and ARNI drugs, and explore the significance of personalized care for elderly patients. Topf also champions the use of AI technology to enhance clinical documentation, making patient care more efficient.
Effective management of hypertension in chronic kidney disease involves adjusting antihypertensive medications and focusing on tailored treatment strategies.
The use of SGLT2 inhibitors is crucial in improving outcomes for diabetes patients with CKD, particularly in advanced disease stages.
Diabetes management for dialysis patients requires a shift from strict glycemic control to a focus on preventing hypoglycemia and individualizing care.
Deep dives
Introduction to Chronic Kidney Disease Management
Blood pressure management plays a critical role in patients with chronic kidney disease (CKD), especially when they transition to dialysis. The podcast discusses a patient case that highlights the complexities of managing a 58-year-old male with CKD, hypertension, and type 2 diabetes experiencing uncontrolled blood pressure. The importance of considering both GFR and albuminuria in classifying CKD is emphasized, with an effective strategy to use algorithms to predict renal prognosis based on these factors. Clinicians are encouraged to communicate risk percentages to patients to foster understanding and engagement in their health management.
The Role of Medication Adjustments
The episode underscores the significance of adjusting antihypertensive medications in CKD patients, stressing the necessity of maintaining optimal blood pressure to prevent cardiovascular events and further renal deterioration. The speakers suggest transitioning patients from hydrochlorothiazide to chlorthalidone and exploring longer-acting angiotensin receptor blockers (ARBs) to enhance blood pressure control. Additionally, they advocate for the use of calcium channel blockers as a supplementary option for managing hypertension. The conversation also highlights the importance of mitigating potential hyperkalemia associated with these medications, particularly in patients transitioning to dialysis.
The Importance of SGLT2 Inhibitors
SGLT2 inhibitors are identified as crucial in managing patients with diabetes and CKD, particularly for those who have progressed to advanced stages of the disease. The discussion notes positive outcomes associated with SGLT2 inhibitors in reducing hospital admissions and improving overall health in patients on dialysis, emphasizing their benefit even at a low GFR. The speakers provide insights from relevant trials that support the use of these agents in maintaining kidney function and reducing cardiovascular risks. This medication class is recognized not just for glycemic control, but for its nephroprotective effects, which can significantly impact patient care.
The Impact of Dialysis on Blood Pressure Management
The podcast explores how the management of blood pressure changes once a patient is on hemodialysis, with an emphasis on obtaining accurate blood pressure readings outside of the dialysis setting. The speakers advocate for a tailored approach, noting that blood pressure medications may need to be withheld on dialysis days to prevent hypotension during treatment sessions. Additionally, the role of maintaining an appropriate 'dry weight' is described as a crucial strategy for minimizing volume overload and hypertension in dialysis patients. Clinicians are encouraged to collaborate closely with nephrologists to ensure consistent and effective blood pressure management across care settings.
Revisiting Diabetes Management in Advanced CKD
Adjustments in diabetes management strategies are highlighted as essential when patients transition to dialysis, with a shift in focus from aggressive glycemic control to preventing harm associated with hypoglycemia. The speakers remind clinicians that while tight glycemic control can avert microvascular complications, it carries risks in dialysis patients due to altered insulin metabolism and reduced gluconeogenesis. Moreover, they discuss the potential benefits of newer diabetes medications, such as GLP-1 receptor agonists, and the importance of understanding patient-specific thresholds for treatment goals. The message reinforces the need to individualize diabetes care based on overall prognosis and quality of life for patients with advanced CKD.
Learn how to manage diabetes and hypertension in chronic kidney disease with expert tips from Kidney Boy, Kashlak’s Chief of Nephrology, Dr. Joef Topf @kidney_boy.
To get this new customer offer and your new 3-month premium wireless plan for just 15 bucks a month, go to mintmobile.com/CURB.
Sponsor: ClinicalKey AI
ClinicalKey AI is an award-winning solution that combines trusted, evidence-based clinical content with conversational search powered by generative AI. To unlock the power of AI in clinical decision-making with ClinicalKey AI, visit Elsevier.health/AI”
Sponsor: Freed
You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
